2013
DOI: 10.1016/j.bcmd.2013.04.005
|View full text |Cite
|
Sign up to set email alerts
|

Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
46
0
1

Year Published

2013
2013
2021
2021

Publication Types

Select...
7
2
1

Relationship

1
9

Authors

Journals

citations
Cited by 66 publications
(51 citation statements)
references
References 21 publications
4
46
0
1
Order By: Relevance
“…I considered a diagnosis of drug-induced tremor, particularly if there was a history of receiving substrate reduction therapy (SRT) with Miglustat, a known cause of tremor (Kuter et al, 2013). In 3/7 tremor cases, SRT had been administered previously but it should be noted that in all cases, tremor was present before the treatment commenced.…”
Section: Discussionmentioning
confidence: 99%
“…I considered a diagnosis of drug-induced tremor, particularly if there was a history of receiving substrate reduction therapy (SRT) with Miglustat, a known cause of tremor (Kuter et al, 2013). In 3/7 tremor cases, SRT had been administered previously but it should be noted that in all cases, tremor was present before the treatment commenced.…”
Section: Discussionmentioning
confidence: 99%
“…Miglustat functions as a glucosylceramide synthase inhibitor and therefore affects the glycosphingolipid pathway. It had previously been approved by the FDA for treatment of Gaucher disease, which is another lysosomal storage disorder characterized by accumulation of glucosylceramide [62].The past several years of experience with miglustat indicate that it is able to stabilize NPC patients and is likely to extend their life spans [44,61].…”
Section: Therapies Tested Previously For Treatment Of Npc Diseasementioning
confidence: 99%
“…An example of this is Miglustat (N-butyldeoxynojirimycin), which is an imino sugar that inhibits glucosylceramide synthase, the first committed step in glycosphingolipid synthesis. Miglustat has been used for treatment of Gaucher disease (Kuter et al 2013).…”
Section: Endosomes and Human Diseasementioning
confidence: 99%